Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Shock in Pediatrics Medication

  • Author: Eric A Pasman, MD; Chief Editor: Timothy E Corden, MD  more...
 
Updated: Mar 03, 2015
 

Medication Summary

A variety of therapeutic treatments may be required for pediatric patients in shock. Possible therapies may include the following:

  • Inotropic medications
  • Dextrose
  • Electrolytes and calcium stabilization
  • Prostaglandin E1
  • Corticosteroids
Next

Inotropic agents

Class Summary

Inotropic agents increase myocardial contractility and have variable effects on peripheral vascular resistance. First-line inotropic agents in pediatric shock include dopamine and epinephrine. On the basis of cardiac output (CO) and systemic vascular resistance (SVR), other vasoactive agents indicated in the treatment of shock may include vasoconstrictors (eg, norepinephrine, phenylephrine) or vasodilators (eg, dobutamine, milrinone).[50, 51] Which agents are indicated and which are effective in patients with any given etiology of shock depends on the end-diastolic volume and contractile state of the patient's cardiovascular system.

Dopamine

 

Dopamine is used for refractory hypotension following adequate volume resuscitation. It stimulates beta1- and alpha1-adrenergic and dopaminergic receptors in a dose-dependent fashion. In low doses, dopamine acts on dopaminergic receptors in renal and splanchnic vascular beds, causing vasodilatation in these beds. In midrange doses, it acts on beta-adrenergic receptors to increase heart rate and contractility, improve cardiac output, and enhance conduction (increasing sinoatrial rate) in the heart. In high doses, it acts on alpha-adrenergic receptors to increase systemic vascular resistance and raise blood pressure.

Dobutamine

 

Sympathomimetic agent with primarily beta1-agonist effects, increasing heart rate and blood pressure. Some weak beta2-mediated peripheral vasodilation. Little effect on alpha receptors. May precipitate ventricular dysrhythmias, although potentially less likely to do so than epinephrine.

Epinephrine (Adrenalin)

 

Epinephrine is used for hypotension refractory to dopamine. Its alpha-agonist effects include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Its beta2-agonist effects include bronchodilation, chronotropic cardiac activity, and positive inotropic effects.

Norepinephrine (Levophed)

 

Norepinephrine is used for protracted hypotension following adequate fluid-volume replacement. This agent stimulates beta1- and alpha-adrenergic receptors, thereby increasing cardiac muscle contractility and heart rate, as well as vasoconstriction.

Phenylephrine

 

Strong alpha-receptor stimulant with little beta-adrenergic activity that produces vasoconstriction of arterioles in the body, helping increase systemic vascular resistance.

Previous
Next

Phosphodiesterase Enzyme Inhibitor

Class Summary

Milrinone is the primary phosphodiesterase (PDE) inhibitor used in pediatrics, and it works via a different mechanism than that of the catecholamines. Milrinone inhibits PDE III, producing an increase in intracellular cyclic adenosine monophosphate (cAMP), which raises intracellular calcium levels and thereby improving cardiac inotropy and peripheral vasodilation.

Milrinone may be used together with catecholamines to further increase myocardial contractility while reducing systemic vascular resistance (SVR) and afterload. It can be useful in improving perfusion in patients who remain in compensated shock with poor peripheral perfusion but a normal central blood pressure and adequate intravascular volume. Milrinone is also often a useful adjunct in patients who have low cardiac output syndrome following congenital heart corrective surgeries.[52]

Adverse effects of milrinone may include arrhythmias and thrombocytopenia.[53, 54] Care must be taken when choosing to start phosphodiesterase inhibitors because of their vasodilator effects and their long half-life.

Milrinone

 

Milrinone is a selective PDE III inhibitor that acts as a positive inotrope and vasodilator with little chronotropic activity.

Previous
Next

Prostaglandins, Endocrine

Class Summary

Neonates who present with shock associated with a large liver, enlarged cardiac silhouette, or heart murmur may have obstructive shock that develops because of closing of the ductus arteriosus. Prior to closure, the ductus arteriosus allows sufficient systemic blood flow to bypass the obstructive lesion. In patients in whom the ductus arteriosus has closed, initiation of prostaglandin E1 to maintain or reestablish its patency may be lifesaving. Adverse effects may include fever, apnea, or hypotension due to vasodilation. Evaluation of cardiac anatomy with echocardiography, performed by a pediatric cardiologist, should be obtained as soon as possible.

Alprostadil IV (Prostin VR)

 

Alprostadil is a synthetic prostaglandin E1 and induces vascular smooth muscle and ductus arteriosus vasodilation. This agent is beneficial in infants with congenital defects that restrict pulmonary or systemic blood flow and in patients who depend on a patent ductus arteriosus for adequate oxygenation and perfusion.

Previous
Next

Corticosteroid

Class Summary

The use of corticosteroids in shock is controversial. However, it is possible that patients in severe septic shock have inadequate levels of circulating glucocorticoids and may benefit from stress dosing of steroids.

Hydrocortisone (Solu-Cortef, Cortef)

 

Hydrocortisone is a glucocorticoid with complex and varied metabolic effects when given systemically. It is the corticosteroid of choice in vasopressor-refractory shock because of its mineralocorticoid activity and glucocorticoid effects.

Previous
 
Contributor Information and Disclosures
Author

Eric A Pasman, MD Resident Physician, Department of Pediatrics, National Capital Consortium, Walter Reed National Military Medical Center

Eric A Pasman, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Nothing to disclose.

Coauthor(s)

Christopher M Watson, MD, MPH Assistant Professor, Department of Pediatrics, Uniformed Services University of the Health Sciences; Adjunct Assistant Professor, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine

Christopher M Watson, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Medical Association, Association of Pediatric Program Directors, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, Wisconsin Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

Barry J Evans, MD Assistant Professor of Pediatrics, Temple University Medical School; Director of Pediatric Critical Care and Pulmonology, Associate Chair for Pediatric Education, Temple University Children's Medical Center

Barry J Evans, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Adam J Schwarz, MD Consulting Staff, Critical Care Division, Pediatric Subspecialty Faculty, Children's Hospital of Orange County

Adam J Schwarz, MD is a member of the following medical societies: American Academy of Pediatrics and Phi Beta Kappa

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Acknowledgments

The views expressed are those of the authors and do not reflect the official policy or position of the US Navy, Department of Defense, or the US Government.

References
  1. Epstein D, Randall CW. Cardiovascular physiology and shock. Nichols DG, ed. Critical Heart Disease in Infants and Children. 2nd Ed. Philadelphia, PA: Mosby Elsevier; 2006. 17-72.

  2. Nadel S, Kissoon N, Ranjit S. Recognition and Initial Management of Shock. Nichols DG, ed. Roger’s Textbook of Pediatric Intensive Care. Philadelphia, PA: Lippincott, William & Wilkins; 2008. 372-383.

  3. Smith LS, Hernan LJ. Shock states. Fuhrman BP, Zimmerman J, eds. Pediatric Critical Care. 4th Ed. Philadelphia, PA: Elsevier Saunders; 2011. 364-378.

  4. American Academy of Pediatrics. Policy statement--child fatality review. Pediatrics. 2010 Sep. 126(3):592-6. [Medline].

  5. [Guideline] Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013. 162(3):193-204. [Medline].

  6. Ackerman AD, Singhi S. Pediatric infectious diseases: 2009 update for the Rogers' Textbook of Pediatric Intensive Care. Pediatr Crit Care Med. 2010 Jan. 11(1):117-23. [Medline].

  7. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005 Jan. 6(1):2-8. [Medline].

  8. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. Jan 2015. 385:117-71. [Medline].

  9. Carcillo JA, Kuch BA, Han YY, Day S, Greenwald BM, McCloskey KA, et al. Mortality and functional morbidity after use of PALS/APLS by community physicians. Pediatrics. 2009 Aug. 124(2):500-8. [Medline].

  10. Fisher JD, Nelson DG, Beyersdorf H, Satkowiak LJ. Clinical spectrum of shock in the pediatric emergency department. Pediatr Emerg Care. 2010 Sep. 26(9):622-5. [Medline].

  11. Balamuth F, Weiss SL, Neuman MI, Scott H, Brady PW, Paul R, et al. Pediatric severe sepsis in U.S. children's hospitals. Pediatr Crit Care Med. 2014 Nov. 15(9):798-805. [Medline]. [Full Text].

  12. American Heart Association. Part 2: Systematic approach to the seriously ill or injured child. Chameides L, Samson RA, Schexnayder SM, Hazinski MF, eds. Pediatric Advanced Life Support Provider Manual. Dallas, TX: American Heart Association; 2011.

  13. Carcillo JA. Capillary refill time is a very useful clinical sign in early recognition and treatment of very sick children. Pediatr Crit Care Med. 2012 Mar. 13(2):210-2. [Medline].

  14. [Guideline] Brierley J, Carcillo JA, Choong K, Cornell T, Decaen A, Deymann A, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009 Feb. 37(2):666-88. [Medline].

  15. [Guideline] Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb. 41(2):580-637. [Medline].

  16. Ferrari M, Mottola L, Quaresima V. Principles, techniques, and limitations of near infrared spectroscopy. Can J Appl Physiol. 2004 Aug. 29(4):463-87. [Medline].

  17. Adcock LM, Wafelman LS, Hegemier S, Moise AA, Speer ME, Contant CF, et al. Neonatal intensive care applications of near-infrared spectroscopy. Clin Perinatol. 1999 Dec. 26(4):893-903, ix. [Medline].

  18. Ghanayem NS, Wernovsky G, Hoffman GM. Near-infrared spectroscopy as a hemodynamic monitor in critical illness. Pediatr Crit Care Med. 2011 Jul. 12(4 Suppl):S27-32. [Medline].

  19. Post F, Weilemann LS, Messow CM, Sinning C, Münzel T. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med. 2008 Nov. 36(11):3030-7. [Medline].

  20. Domico M, Liao P, Anas N, Mink RB. Elevation of brain natriuretic peptide levels in children with septic shock. Pediatr Crit Care Med. 2008 Sep. 9(5):478-83. [Medline].

  21. Wong HR, Salisbury S, Xiao Q, Cvijanovich NZ, Hall M, Allen GL, et al. The pediatric sepsis biomarker risk model. Crit Care. 2012 Oct 1. 16(5):R174. [Medline]. [Full Text].

  22. Wong HR, Weiss SL, Giuliano JS Jr, Wainwright MS, Cvijanovich NZ, Thomas NJ, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS One. 2014. 9(1):e86242. [Medline]. [Full Text].

  23. [Guideline] de Oliveira CF, de Oliveira DS, Gottschald AF, Moura JD, Costa GA, Ventura AC, et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med. 2008 Jun. 34(6):1065-75. [Medline].

  24. Sankar J, Sankar MJ, Suresh CP, Dubey NK, Singh A. Early goal-directed therapy in pediatric septic shock: comparison of outcomes "with" and "without" intermittent superior venacaval oxygen saturation monitoring: a prospective cohort study*. Pediatr Crit Care Med. 2014 May. 15(4):e157-67. [Medline].

  25. Dias CR, Leite HP, Nogueira PC, Brunow de Carvalho W. Ionized hypocalcemia is an early event and is associated with organ dysfunction in children admitted to the intensive care unit. J Crit Care. 2013 Oct. 28(5):810-5. [Medline].

  26. Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr. 1990 Dec. 117(6):986-9. [Medline].

  27. Meert KL, Donaldson A, Nadkarni V, Tieves KS, Schleien CL, Brilli RJ, et al. Multicenter cohort study of in-hospital pediatric cardiac arrest. Pediatr Crit Care Med. 2009 Sep. 10(5):544-53. [Medline]. [Full Text].

  28. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA. 1991 Sep 4. 266(9):1242-5. [Medline].

  29. Ranjit S, Kissoon N, Jayakumar I. Aggressive management of dengue shock syndrome may decrease mortality rate: a suggested protocol. Pediatr Crit Care Med. 2005 Jul. 6(4):412-9. [Medline].

  30. Oliveira CF, Nogueira de Sá FR, Oliveira DS, Gottschald AF, Moura JD, Shibata AR, et al. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world. Pediatr Emerg Care. 2008 Dec. 24(12):810-5. [Medline].

  31. Voigt J, Waltzman M, Lottenberg L. Intraosseous vascular access for in-hospital emergency use: a systematic clinical review of the literature and analysis. Pediatr Emerg Care. 2012 Feb. 28(2):185-99. [Medline].

  32. Cole ET, Harvey G, Urbanski S, Foster G, Thabane L, Parker MJ. Rapid paediatric fluid resuscitation: a randomised controlled trial comparing the efficiency of two provider-endorsed manual paediatric fluid resuscitation techniques in a simulated setting. BMJ Open. 2014 Jul 3. 4(7):e005028. [Medline]. [Full Text].

  33. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30. 364(26):2483-95. [Medline].

  34. Abulebda K, Cvijanovich NZ, Thomas NJ, Allen GL, Anas N, Bigham MT, et al. Post-ICU admission fluid balance and pediatric septic shock outcomes: a risk-stratified analysis. Crit Care Med. 2014 Feb. 42(2):397-403. [Medline]. [Full Text].

  35. Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med. 2014 Nov. 42(11):2409-17. [Medline]. [Full Text].

  36. [Guideline] Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, et al. Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics. 2010 Nov. 126(5):e1361-99. [Medline].

  37. Hanna W, Wong HR. Pediatric sepsis: challenges and adjunctive therapies. Crit Care Clin. 2013 Apr. 29(2):203-22. [Medline]. [Full Text].

  38. Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16. 9:CD001090. [Medline].

  39. Kissoon N, Carcillo JA, Espinosa V, Argent A, Devictor D, Madden M, et al. World Federation of Pediatric Intensive Care and Critical Care Societies: Global Sepsis Initiative. Pediatr Crit Care Med. 2011 Sep. 12(5):494-503. [Medline].

  40. Zimmerman JJ, Williams MD. Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. Pediatr Crit Care Med. 2011 Jan. 12(1):2-8. [Medline].

  41. Atkinson SJ, Cvijanovich NZ, Thomas NJ, Allen GL, Anas N, Bigham MT, et al. Corticosteroids and pediatric septic shock outcomes: a risk stratified analysis. PLoS One. 2014. 9(11):e112702. [Medline]. [Full Text].

  42. Menon K, McNally D, Choong K, Sampson M. A systematic review and meta-analysis on the effect of steroids in pediatric shock. Pediatr Crit Care Med. 2013 Jun. 14(5):474-80. [Medline].

  43. Pizarro CF, Troster EJ, Damiani D, Carcillo JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med. 2005 Apr. 33(4):855-9. [Medline].

  44. Schotola H, Toischer K, Popov AF, Renner A, Schmitto JD, Gummert J, et al. Mild metabolic acidosis impairs the ß-adrenergic response in isolated human failing myocardium. Crit Care. 2012 Aug 13. 16(4):R153. [Medline]. [Full Text].

  45. Mathieu D, Neviere R, Billard V, Fleyfel M, Wattel F. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med. 1991 Nov. 19(11):1352-6. [Medline].

  46. Aschner JL, Poland RL. Sodium bicarbonate: basically useless therapy. Pediatrics. 2008 Oct. 122(4):831-5. [Medline].

  47. Paden ML, Rycus PT, Thiagarajan RR. Update and outcomes in extracorporeal life support. Semin Perinatol. 2014 Mar. 38(2):65-70. [Medline].

  48. DiCarlo JV, Dudley TE, Sherbotie JR, Kaplan BS, Costarino AT. Continuous arteriovenous hemofiltration/dialysis improves pulmonary gas exchange in children with multiple organ system failure. Crit Care Med. 1990 Aug. 18(8):822-6. [Medline].

  49. Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med. 2004 Aug. 32(8):1771-6. [Medline].

  50. Vogt W, Laer S. Prevention for pediatric low cardiac output syndrome: results from the European survey EuLoCOS-Paed. Paediatr Anaesth. 2011 Dec. 21(12):1176-84. [Medline].

  51. Hoffman TM. Newer inotropes in pediatric heart failure. J Cardiovasc Pharmacol. 2011 Aug. 58(2):121-5. [Medline].

  52. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003 Feb 25. 107(7):996-1002. [Medline].

  53. Meyer S, Gortner L, Brown K, Abdul-Khaliq H. The role of milrinone in children with cardiovascular compromise: review of the literature. Wien Med Wochenschr. 2011 Apr. 161(7-8):184-91. [Medline].

  54. Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev. 2010 Nov 10. CD007802. [Medline].

 
Previous
Next
 
Chest radiograph in a patient with cardiomegaly, which may accompany cardiogenic shock.
Determinants of cardiac function and oxygen delivery to tissues. FiO2 = fraction of inspired oxygen. Adapted from Strange GR. APLS: The Pediatric Emergency Medicine Course. 3rd ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1998:34.
Hemodynamic response to shock hemorrhage model (based on normal data). Adapted from Schwaitzberg SD, Bergman KS, Harris BH. A pediatric trauma model of continuous hemorrhage. J Pediatr Surg. Jul 1988;23(7):605-9.
Pediatric shock management algorithm. ACTH = adrenocorticotropic hormone; CI = cardiac index; ECMO = extracorporeal membrane oxygenation; MAP-CVP = mean arterial pressure-central venous pressure; PALS = Pediatric Advanced Life Support; PDE = phosphodiesterase; PICU = pediatric intensive care unit; SVC O2 = superior vena cava oxygen saturation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.